• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Screening
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

BREAKING NEWS: British Analysis Does Not Confirm Rosiglitazone (Avandia) MI Risk

Article

NEWCASTLE UPON TYNE, England, June 5 -- An interim analysis of the 4,447-patient RECORD trial did not confirman increased risk of myocardial infarction or cardiac death in patients taking rosiglitazone (Avandia) for treatment of type 2 diabetes, although the data suggest an increased risk of heart failure. So reported the New England Journal of Medicine online today, one day before a Congressional hearing on the safety of rosiglitazone.

NEWCASTLE UPON TYNE, England, June 5 -- An interim analysis of the 4,447-patient RECORD trial did not confirman increased risk of myocardial infarction or cardiac death in patients taking rosiglitazone (Avandia) for treatment of type 2 diabetes, although the data suggest an increased risk of heart failure. So reported the New England Journal of Medicine online today, one day before a Congressional hearing on the safety of rosiglitazone.

Recent Videos
Related Content
Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose / image credit: ©New Africa/AdobeStock

Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose

Sydney Jennings
September 26th 2024
Article

Your daily dose of the clinical news you may have missed.

Site Logo

Women and Heart Disease: Incidence, Prevalence, Progress, and the Future

C Noel Bairey Merz, MD;Payal Kohli, MD
April 6th 2013
Podcast

Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women

Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose / image credit: ©New Africa/AdobeStock

Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose

Sydney Jennings
May 2nd 2024
Article

Your daily dose of the clinical news you may have missed.

The Great Beta-Blocker Debate: The Pros and Cons

The Great Beta-Blocker Debate: The Pros and Cons

Gregory W. Rutecki, MD;Bradley Wright, PharmD
December 12th 2012
Podcast

Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.

/ image credit internal bleeding ©Artur/stock.adobe.com

Concomitant SSRI and DOAC Use Increases Risk of Major Bleeding, Including ICH: New Findings

Grace Halsey
March 25th 2024
Article

Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.

Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose / image credit: ©New Africa/AdobeStock

Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose

Sydney Jennings
February 19th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.